Metabolic correlates of olfactory dysfunction in COVID-19 and Parkinson's disease (PD) do not overlap.
Anosmia
Brain PET
COVID-19
Parkinson’s disease
[18F]FDG
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
09
09
2021
accepted:
19
12
2021
pubmed:
6
1
2022
medline:
21
4
2022
entrez:
5
1
2022
Statut:
ppublish
Résumé
Hyposmia is a common feature of COVID-19 and Parkinson's disease (PD). As parkinsonism has been reported after COVID-19, a link has been hypothesized between SARS-CoV2 infection and PD. We aimed to evaluate brain metabolic correlates of isolated persistent hyposmia after mild-to-moderate COVID-19 and to compare them with metabolic signature of hyposmia in drug-naïve PD patients. Forty-four patients who experienced hyposmia after SARS-COV2 infection underwent brain [ COVID-hyposmia patients (n = 21) exhibited significant hypometabolism in the bilateral gyrus rectus and orbitofrontal cortex with respect to COVID-non-hyposmia (n = 23) (p < 0.002) and in middle and superior temporal gyri, medial/middle frontal gyri, and right insula with respect to PD-hyposmia (p < 0.012). With respect to COVID-hyposmia, PD-hyposmia patients showed hypometabolism in inferior/middle occipital gyri and cuneus bilaterally. Olfactory test scores were directly correlated with metabolism in bilateral rectus and medial frontal gyri and in the right middle temporal and anterior cingulate gyri in COVID-hyposmia patients (p < 0.006) and with bilateral cuneus/precuneus and left lateral occipital cortex in PD-hyposmia patients (p < 0.004). Metabolic signature of persistent hyposmia after COVID-19 encompasses cortical regions involved in olfactory perception and does not overlap metabolic correlates of hyposmia in PD.
Identifiants
pubmed: 34984501
doi: 10.1007/s00259-021-05666-9
pii: 10.1007/s00259-021-05666-9
pmc: PMC8727173
doi:
Substances chimiques
RNA, Viral
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1939-1950Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, Kneen R, Defres S, Sejvar J, Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–83.
doi: 10.1016/S1474-4422(20)30221-0
pubmed: 32622375
pmcid: 7332267
Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277:2251–61.
doi: 10.1007/s00405-020-05965-1
pubmed: 32253535
pmcid: 7134551
Boscolo-Rizzo P, Polesel J, Spinato G, Menegaldo A, Fabbris C, Calvanese L, Borsetto D, Hopkins C. Predominance of an altered sense of smell or taste among long-lasting symptoms in patients with mildly symptomatic COVID-19. Rhinology. 2020;58:524–5.
doi: 10.4193/Rhin20.263
pubmed: 32683438
Estiri H, Strasser ZH, Brat GA, Semenov YR, Patel CJ, Murphy SN. Evolving phenotypes of non-hospitalized patients that indicate long COVID 2021. https://doi.org/10.1101/2021.04.25.21255923
Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020;9:100163.
doi: 10.1016/j.bbih.2020.100163
pubmed: 33111132
pmcid: 7581383
Guedj E, Lazarini F, Morbelli S, Ceccaldi M, Hautefort C, Kas A, Radulesco T, Salmon-Ceron D, Eldin C. Long COVID and the brain network of Proust’s madeleine: targeting the olfactory pathway. Clin Microbiol Infect. 2021. https://doi.org/10.1016/j.cmi.2021.05.015 .
doi: 10.1016/j.cmi.2021.05.015
pubmed: 34592419
pmcid: 8473066
Morbelli S, Ekmekcioglu O, Barthel H, Albert NL, Boellaard R, Cecchin D, Guedj E, Lammertsma AA, Law I, Penuelas I, Semah F, Traub-Weidinger T, van de Giessen E, Varrone A, Garibotto V, EANM Neuroimaging Committee. COVID-19 and the brain: impact on nuclear medicine in neurology. Eur J Nucl Med Mol Imaging. 2020;47:2487–92.
doi: 10.1007/s00259-020-04965-x
pubmed: 32700058
pmcid: 7375837
Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, Raoult D. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur J Nucl Med Mol Imaging. 2021;48:592–5.
doi: 10.1007/s00259-020-04973-x
pubmed: 32728799
Niesen M, Trotta N, Noel A, Coolen T, Fayad G, Leurkin-Sterk G, Delpierre I, Henrard S, Sadeghi N, Goffard JC, Goldman S, De Tiège X. Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell. Eur J Nucl Med Mol Imaging. 2021;48:1890–901.
doi: 10.1007/s00259-020-05154-6
pubmed: 33398411
pmcid: 7781559
Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, Guis S, Barthelemy F, Habert P, Ceccaldi M, Million M, Raoult D, Cammilleri S, Eldin C. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. 2021;48:2823–33.
doi: 10.1007/s00259-021-05215-4
pubmed: 33501506
pmcid: 7837643
Yousefi-Koma A, Haseli S, Bakhshayeshkaram M, Raad N, Karimi-Galougahi M. Multimodality imaging with PET/CT and MRI reveals hypometabolism in tertiary olfactory cortex in parosmia of COVID-19. Acad Radiol. 2021;28:749–51.
doi: 10.1016/j.acra.2021.01.031
pubmed: 33582030
pmcid: 7857079
Sollini M, Morbelli S, Ciccarelli M, Cecconi M, Aghemo A, Morelli P, Chiola S, Gelardi F, Chiti A. Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study. Eur J Nucl Med Mol Imaging. 2021;7:1–11.
Blazhenets G, Schroeter N, Bormann T, Thurow J, Wagner D, Frings L, Weiller C, Meyer PT, Dressing A, Hosp JA. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med. 2021;62:910–5.
doi: 10.2967/jnumed.121.262128
pubmed: 33789937
pmcid: 8882885
Donegani MI, Miceli A, Pardini M, Bauckneht M, Chiola S, Pennone M, Marini C, Massa F, Raffa S, Ferrarazzo G, Arnaldi D, Sambuceti G, Nobili F, Morbelli S. Brain metabolic correlates of persistent olfactory dysfunction after SARS-Cov2 infection. Biomedicines. 2021;9:287.
doi: 10.3390/biomedicines9030287
pubmed: 33808956
pmcid: 7998481
Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, Thurow J, Wagner D, Waller C, Niesen WD, Frings L, Urbach H, Prinz M, Weiller C, Schroeter N, Meyer PT. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 202;144:1263–1276.
Varghese J, Sandmann S, Ochs K, Schrempf IM, Frömmel C, Dugas M, Schmidt HH, Vollenberg R, Tepasse PR. Persistent symptoms and lab abnormalities in patients who recovered from COVID-19. Sci Rep. 2021;11:12775.
doi: 10.1038/s41598-021-91270-8
pubmed: 34140539
pmcid: 8211641
Mesholam RI, Moberg PJ, Mahr RN, Doty RL. Olfaction in neurodegenerative disease: a meta-analysis of olfactory functioning in Alzheimer’s and Parkinson’s diseases. Arch Neurol. 1998;55:84–90.
doi: 10.1001/archneur.55.1.84
pubmed: 9443714
Utsumi K, Fukatsu R, Yamada R, Takamaru Y, Hara Y, Yasumura S. Characteristics of initial symptoms and symptoms at diagnosis in probable dementia with Lewy body disease: incidence of symptoms and gender differences. Psychogeriatrics. 2020;20(5):737–45.
doi: 10.1111/psyg.12586
pubmed: 32743894
Walker IM, Fullard ME, Morley JF, Duda JE. Olfaction as an early marker of Parkinson’s disease and Alzheimer’s disease. Handb Clin Neurol. 2021;182:317–29.
doi: 10.1016/B978-0-12-819973-2.00030-7
pubmed: 34266602
Nobili F, Morbelli S, Arnaldi D, Ferrara M, Campus C, Brugnolo A, Mazzei D, Mehrdad N, Sambuceti G, Rodriguez G. Radionuclide brain imaging correlates of cognitive impairment in Parkinson’s disease (PD). J Neurol Sci. 2011;310:31–5.
doi: 10.1016/j.jns.2011.06.053
pubmed: 21762928
Meles SK, Renken RJ, Pagani M, Teune LK, Arnaldi D, Morbelli S, Nobili F, van Laar T, Obeso JA, Rodríguez-Oroz MC, Leenders KL. Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts. Eur J Nucl Med Mol Imaging. 2020;47:437–50.
doi: 10.1007/s00259-019-04570-7
pubmed: 31768600
Rebholz H, Braun RJ, Ladage D, Knoll W, Kleber C, Hassel AW. Loss of olfactory function-early indicator for COVID-19, other viral infections and neurodegenerative disorders. Front Neurol. 2020;11:569333.
doi: 10.3389/fneur.2020.569333
pubmed: 33193009
pmcid: 7649754
Merello M, Bhatia KP, Obeso JA. SARS-CoV-2 and the risk of Parkinson’s disease: facts and fantasy. Lancet Neurol. 2021;20:94–5.
doi: 10.1016/S1474-4422(20)30442-7
pubmed: 33253627
Morassi M, Palmerini F, Nici S, Magni E, Savelli G, Guerra UP, Chieregato M, Morbelli S, Vogrig A. SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol. 2021;21:1–8.
Makhoul K, Jankovic J. Parkinson’s disease after COVID-19. J Neurol Sci. 2021;422:117331.
doi: 10.1016/j.jns.2021.117331
pubmed: 33540185
Cohen ME, Eichel R, Steiner-Birmanns B, et al. A case of probable Parkinson’s disease after SARS-CoV-2 infection. Lancet Neurol. 2020;19:804–5.
doi: 10.1016/S1474-4422(20)30305-7
pubmed: 32949534
pmcid: 7494295
Faber I, Brandão PRP, Menegatti F, et al. Coronavirus disease 2019 and parkinsonism: a non-post-encephalitic case. Mov Disord. 2020;35:1721–2.
doi: 10.1002/mds.28277
pubmed: 32815213
Gandhi RT, Lynch JB, del Rio C. Mild or moderate COVID-19. NEJM. 2020;383(18):1757e66.
doi: 10.1056/NEJMcp2009249
Orso B, Arnaldi D, Girtler N, Brugnolo A, Doglione E, Mattioli P, Biassoni E, Fancellu R, Massa F, Bauckneht M, Chiola S, Morbelli S, Nobili F, Pardini M. Dopaminergic and serotonergic degeneration and cortical [18F]fluorodeoxyglucose positron emission tomography in de novo Parkinson’s disease. Mov Disord. 2021. https://doi.org/10.1002/mds.28654 (Epub ahead of print).
doi: 10.1002/mds.28654
pubmed: 34533239
Kobal G, Hummel T, Sekinger B, et al. “Sniff Sticks”: screening of olfactory performance. Rhinology. 1996;34:222–6.
pubmed: 9050101
Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. Updated Sniffin’ Sticks normative data based on an extended sample of 9139 subjects. Eur Arch Otorhinolaryngol. 2019;276:719–28.
doi: 10.1007/s00405-018-5248-1
pubmed: 30554358
Briner HR, Simmen D. Smell diskettes as screening test of olfaction. Rhinology. 1999;37:145–8.
pubmed: 10670026
Arnaldi D, Morbelli S, Brugnolo A, Girtler N, Picco A, Ferrara M, Accardo J, Buschiazzo A, de Carli F, Pagani M, Nobili F. Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson’s disease and probable RBD. Parkinsonism Relat Disord. 2016;29:47–53.
doi: 10.1016/j.parkreldis.2016.05.031
pubmed: 27264343
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10.
doi: 10.1007/s00259-009-1264-0
pubmed: 19838705
Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RS. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1994;2:189–210.
doi: 10.1002/hbm.460020402
Morbelli S, Piccardo A, Villavecchia G, Dessi B, Brugnolo A, Piccini A, Caroli A, Frisoni G, Rodriguez G, Nobili F. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging. 2010;37:36–45.
doi: 10.1007/s00259-009-1218-6
pubmed: 19662411
Toniolo S, Scarioni M, Di Lorenzo F, Hort J, Georges J, Tomic S, Nobili F, Frederiksen KS, Management Group of the EAN Dementia and Cognitive Disorders Scientific Panel. Dementia and COVID-19, a bidirectional liaison: risk factors, biomarkers, and optimal health care. J Alzheimers Dis. 2021. https://doi.org/10.3233/JAD-210335 (Epub ahead of print).
doi: 10.3233/JAD-210335
pubmed: 34092646
Tiraboschi P, Corso A, Guerra UP, Nobili F, Piccardo A, Calcagni ML, Volterrani D, Cecchin D, Tettamanti M, Antelmi L, Vidale S, Sacco L, Merello M, Stefanini S, Micheli A, Vai P, Capitanio S, Gabanelli SV, Riva R, Pinto P, Biffi AM, Muscio C, SCILLA Working Group. (123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with Lewy bodies from other dementias: A comparative study. Ann Neurol. 2016;80:368–78.
doi: 10.1002/ana.24717
pubmed: 27398636
Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, Brooks DJ, Darcourt J, Dickson JC, Douglas D, Drzezga A, Dubroff J, Ekmekcioglu O, Garibotto V, Herscovitch P, Kuo P, Lammertsma A, Pappata S, Peñuelas I, Seibyl J, Semah F, Tossici-Bolt L, Van de Giessen E, Van Laere K, Varrone A, Wanner M, Zubal G, Law I. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912.
doi: 10.1007/s00259-020-04817-8
pubmed: 32388612
pmcid: 7300075
Helmich RC, Bloem BR. The impact of the COVID-19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Park Dis. 2020;10:351–4.
Hainque E, Grabli D. Rapid worsening in Parkinson’s disease may hide COVID-19 infection. Parkinsonism Relat Disord. 2020;S1353–8020:30117–26.
Paschen L, Schmidt N, Wolff S, Cnyrim C, van Eimeren T, Zeuner KE, et al. The olfactory bulb volume in patients with idiopathic Parkinson’s disease. Eur J Neurol. 2015;22:1068–73.
doi: 10.1111/ene.12709
pubmed: 25912367
Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. JAMA Neurol. 2020;77:1028–9.
doi: 10.1001/jamaneurol.2020.2125
pubmed: 32469400
Crespo Cuevas AM, Ispierto L, Vilas D, Planas A, Planas A, Isern I, Sanchez J, De Haro J, Alvarez R. Distinctive olfactory pattern in Parkinson’s disease and non-neurodegenerative causes of hyposmia. Neurodegener Dis. 2018;18:143–9.
doi: 10.1159/000488680
pubmed: 29940577
Haghshomar M, Dolatshahi M, Ghazi Sherbaf F, Sanjari Moghaddam H, Shirin Shandiz M, Aarabi MH. Disruption of inferior longitudinal fasciculus microstructure in Parkinson’s disease: a systematic review of diffusion tensor imaging studies. Front Neurol. 2018;9:598.
doi: 10.3389/fneur.2018.00598
pubmed: 30093877
pmcid: 6070770
Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, Frey KA. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain. 2010;133:1747–54.
doi: 10.1093/brain/awq079
pubmed: 20413575
pmcid: 2877903
Postuma R, Gagnon JF. Cognition and olfaction in Parkinson’s disease. Brain. 2010;133:e160.
doi: 10.1093/brain/awq225
pubmed: 20805099
Richard L. Doty, Olfaction in Richard L. Doty, Olfaction, Editor(s). Encyclopedia of the human brain, Academic Press, 2002; 717–727, ISBN 9780122272103,
Gao X, Wu D, Li X, Su B, Sun Z, Nie B, Zhang X, Wei Y. Altered glucose metabolism of the olfactory-related cortices in anosmia patients with traumatic brain injury. Eur Arch Otorhinolaryngol. 2021. https://doi.org/10.1007/s00405-021-06754-0 (Epub ahead of print).
doi: 10.1007/s00405-021-06754-0
pubmed: 34816297
Chiaravalloti A, Pagani M, Micarelli A, Di Pietro B, Genovesi G, Alessandrini M, Schillaci O. Cortical activity during olfactory stimulation in multiple chemical sensitivity: a (18)F-FDG PET/CT study. Eur J Nucl Med Mol Imaging. 2015;42:733–40.
doi: 10.1007/s00259-014-2969-2
pubmed: 25690545
Chu WJ, Mason GF, Pan JW, Hetherington HP, Liu HG, San Pedro EC, Mountz JM. Regional cerebral blood flow and magnetic resonance spectroscopic imaging findings in diaschisis from stroke. Stroke. 2002;33:1243–8.
doi: 10.1161/01.STR.0000015240.75199.BE
pubmed: 11988598
Dietemann S, Noblet V, Imperiale A, Blondet C, Namer IJ. FDG PET findings of the brain in sudden blindness caused by bilateral central retinal artery occlusion revealing giant cell arteritis. Clin Nucl Med. 2015;40:45–6.
doi: 10.1097/RLU.0000000000000598
pubmed: 25275418
Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 syndrome: the persistent symptoms at the post-viral stage of the disease. A systematic review of the current data. Front Med (Lausanne). 2021;8:653516.
doi: 10.3389/fmed.2021.653516
pubmed: 34017846
pmcid: 8129035
Antczak J, Popp R, Hajak G, Zulley J, Marienhagen J, Geisler P. Positron emission tomography findings in obstructive sleep apnea patients with residual sleepiness treated with continuous positive airway pressure. J Physiol Pharmacol. 2007;5(Suppl. 5):25–35.